| Company Name | Pfizer |
|---|---|
| Protocol Number | B0661116 |
| Title of Study | Thromboembolic and Bleeding Risks of Apixaban, Rivaroxaban and Dabigatran versus Warfarin in Patients with Non-Valvular Atrial Fibrillation |
| Primary Objective | 1. Describe clinical and demographic characteristics of OAC treatment naïve patients who were prescribed with warfarin, dabigatran, rivaroxaban or apixaban 2. Compare the safety and effectiveness for OAC treatment naïve patients prescribed dabigatran, rivaroxaban and apixaban or warfarin |
| Number of Sites | NA (健保資料庫回溯性研究) |
| Period of Study | From：2018/8/8 to：2019/8/7 |
| Number of Patients | NA (健保資料庫回溯性研究)人 |
| IRB Approval Date | 2018/8/8 |
| Publication Plan / Date | 2019/12/31 |
